Researchers in the article tested a new drug called Dersimelagon for patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These two rare diseases cause inflammation, cell damage, and severe pain when patients are exposed to the sun. EPP and XLP affect one in every 75,000 to 200,000 white people, according to the researchers' study. Based on the survey, Dersimelagon medicine is more accessible for children and for those patients who cannot easily get to medical appointments for new implants. According to adults with EPP or XLP who tested the drug, taking the medicine increased the amount of time they could spend in the sun before developing "prodromal" symptoms. However, just like other medications, the drug also has side effects, including nausea, freckles, and headaches, but they are short-lived and well-tolerated.
I thought the main article I read was concise, where the report mainly focused on the effects of the new drug that was tested on the patients, how accessible it can be for people who do not have advanced medical treatment, and how it can lessen the pain of patients' exposure to sunlight. The second article gave more information about the cause and effect of the Dersimelagon drug on patients with EPP and XLP. The article was also insightful since the research summary also explained the diseases, the treatment procedures, and how clinical problems can be prevented.
Sources:
[2] https://www.nejm.org/doi/10.1056/NEJMoa2208754
No comments:
Post a Comment